Crossmark

Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development

Published Online: 2021-05-27

Published Print: 2021-09

Authors

Ménard, Timothé https://orcid.org/0000-0003-4545-6944
Barros, Alaina

Ganter, Christopher https://orcid.org/0000-0002-0519-0718
License Information

Text and Data Mining valid from 2021-05-27

Version of Record valid from 2021-05-27
More Information

Article History

Received: 23 February 2021

Accepted: 19 May 2021

First Online: 27 May 2021

Declarations

:

: Timothé Ménard, Alaina Barros and Christopher Ganter were employees of Roche/Genentech at the time this research was completed.

Document is current